Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Authors: Shadman, Mazyar, Manzoor, Beenish S., Sail, Kavita, Tuncer, Hande H., Allan, John N., Ujjani, Chaitra, Emechebe, Nnadozie, Kamalakar, Rajesh, Coombs, Catherine C., Leslie, Lori, Barr, Paul M., Brown, Jennifer R., Eyre, Toby A., Rampotas, Alexandros, Schuh, Anna, Lamanna, Nicole, Skarbnik, Alan, Roeker, Lindsey E., Bannerji, Rajat, Eichhorst, Barbara, Fleury, Isabelle, Davids, Matthew S., Alhasani, Hasan, Jiang, Dingfeng, Hill, Brian T., Schuster, Stephen J., Brander, Danielle M., Pivneva, Irina, Burne, Rebecca, Guerin, Annie, Mato, Anthony R.

Source: Clinical lymphoma, myeloma & leukemia. 23(7):515-526

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100193422989.0x000001&indx=1&recIds=ETOCvdc_100193422989.0x000001

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Authors: Lasater, Elisabeth A., Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Barrett, Kathy, Rys, Ryan N., Oeh, Jason, Lin, Eva, Sterne‐Weiler, Tim, Ingalla, Ellen Rei, Go, MaryAnn, Yu, Shang‐Fan, Krem, Maxwell M., Arthur, Chris, Hahn, Uwe, Johnston, Anna, Karur, Vinit, Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Polson, Andrew G., Chang, YiMeng, Wever, Claudia, Johnson, Nathalie A., Jiang, Yanwen, Hirata, Jamie, Sampath, Deepak, Musick, Lisa, Flowers, Christopher R., Wertz, Ingrid E.

Source: American journal of hematology. 98(3):449-463

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100175747561.0x000001&indx=1&recIds=ETOCvdc_100175747561.0x000001

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Authors: Bannerji, Rajat, Arnason, Jon E, Advani, Ranjana H, Brown, Jennifer R, Allan, John N, Ansell, Stephen M, Barnes, Jeffrey A, O'Brien, Susan M, Chávez, Julio C, Duell, Johannes, Rosenwald, Andreas, Crombie, Jennifer L, Ufkin, Melanie, Li, Jingjin, Zhu, Min, Ambati, Srikanth R, Chaudhry, Aafia, Lowy, Israel, Topp, Max S

Source: Lancet.Haematology. 9(5):e327-e339

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183247417.0x000001&indx=1&recIds=ETOCvdc_100183247417.0x000001

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Authors: Tam, Constantine S., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Jacobs, Ryan, Opat, Stephen, Barr, Paul M., Tedeschi, Alessandra, Trentin, Livio, Bannerji, Rajat, Jackson, Sharon, Kuss, Bryone J., Moreno, Carol, Szafer-Glusman, Edith, Russell, Kristin, Zhou, Cathy, Ninomoto, Joi, Dean, James P., Wierda, William G., Ghia, Paolo

Source: Blood. 139(22):3278-3289

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183252758.0x000001&indx=1&recIds=ETOCvdc_100183252758.0x000001

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Authors: Gregory, Gareth P. ^*, Kumar, Shaji, Wang, Ding, Mahadevan, Daruka, Walker, Patricia, Wagner-Johnston, Nina, Escobar, Carolina, Bannerji, Rajat, Bhutani, Divaya, Chang, Julie, Hernandez-Ilizaliturri, Francisco J., Klein, Andreas, Pagel, John M., Rybka, Witold, Yee, Andrew J., Mohrbacher, Anne, Huang, Mo, Farooqui, Mohammed, Marinello, Patricia, Quach, Hang

Source: In Blood Advances 22 February 2022 6(4):1232-1242

Impact of Insurance Status on Survival Outcomes in Adults With Acute Lymphoblastic Leukemia (ALL): A Single-center Experience

Authors: Krakora, Rebecca, Shih, Weichung, Popli, Pallvi, Gorshein, Elan, Salaru, Gratian, Moore, Dirk, Chen, Chunxia, David, Kevin, Bannerji, Rajat

Source: In Clinical Lymphoma, Myeloma and Leukemia November 2020 20(11):e890-e896

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma.

Authors: Yuen, Sam, Phillips, Tycel J., Bannerji, Rajat, Marlton, Paula, Gritti, Giuseppe, Seymour, John F., Johnston, Anna, Arthur, Christopher, Dodero, Anna, Sharma, Sunil, Hirata, Jamie, Musick, Lisa, Flowers, Christopher R.

Source: American Journal of Hematology; Jul2024, Vol. 99 Issue 7, p1281-1289, 9p

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Authors: Crombie, Jennifer L., Graff, Tara, Falchi, Lorenzo, Karimi, Yasmin H., Bannerji, Rajat, Nastoupil, Loretta, Thieblemont, Catherine, Ursu, Renata, Bartlett, Nancy, Nachar, Victoria, Weiss, Jonathan, Osterson, Jane, Patel, Krish, Brody, Joshua, Abramson, Jeremy S., Lunning, Matthew, Shah, Nirav N., Ayed, Ayed, Kamdar, Manali, Parsons, Benjamin, Caimi, Paolo, Flinn, Ian, Herrera, Alex, Sharman, Jeffrey, McKenna, Marshall, Armand, Philippe, Kahl, Brad, Smith, Sonali, Zelenetz, Andrew, Budde, Lihua Elizabeth, Hutchings, Martin, Phillips, Tycel, Dickinson, Michael

Source: In Blood 18 April 2024 143(16):1565-1575

Choline-magnesium trisalicylate modulates acute myelogenous leukemia gene expression during induction chemotherapy

Authors: Medina, Daniel, David, Kevin, Lin, Yong, Schaar, Dale, Patel, Vimal, Gharibo, Mecide, Bannerji, Rajat, Walton, Kelly, Aisner, Joseph, Rabson, Arnold B., Strair, Roger

Source: Leukemia & lymphoma. 58(5):1227-1230

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100048549014.0x000001&indx=1&recIds=ETOCvdc_100048549014.0x000001

POSTER: IBCL-485 A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

Authors: Salles, Gilles, Shah, Harsh, Leonard, John P., Szanto, Attila, Chen, Jade, Bannerji, Rajat, Morschhauser, Franck, Nastoupil, Loretta J.

Source: Clinical lymphoma, myeloma & leukemia. 23(S1):S209-S209

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100196318200.0x000001&indx=1&recIds=ETOCvdc_100196318200.0x000001

Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast Cancer

Authors: Mita, Monica M., Joy, Anil A., Mita, Alain, Sankhala, Kamalesh, Jou, Ying-Ming, Zhang, Da, Statkevich, Paul, Zhu, Yali, Yao, Siu-Long, Small, Karen, Bannerji, Rajat, Shapiro, Charles L.

Source: In Clinical Breast Cancer June 2014 14(3):169-176

Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Authors: Stephenson, Joe J., Nemunaitis, John, Joy, Anil A., Martin, Julie C., Jou, Ying-Ming, Zhang, Da, Statkevich, Paul, Yao, Siu-Long, Zhu, Yali, Zhou, Honghong, Small, Karen, Bannerji, Rajat, Edelman, Martin J.

Source: In Lung Cancer February 2014 83(2):219-223

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models

Authors: Feldmann, Georg, Mishra, Anjali, Bisht, Savita, Karikari, Collins, Garrido-Laguna, Ignacio, Rasheed, Zeshaan, Ottenhof, NIki A., Dadon, Tikva, Alvarez, Hector, Fendrich, Volker, Rajeshkumar, N.V., Matsui, William, Brossart, Peter, Hidalgo, Manuel, Bannerji, Rajat, Maitra, Anirban, Nelkin, Barry D.

Source: Cancer biology & therapy. 12(7):598-609

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100053903910.0x000001&indx=1&recIds=ETOCvdc_100053903910.0x000001

Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)

Authors: Zheng, Dandan ^*, Sail, Kavita ^*, Roeker, Lindsey E, Manzoor, Beenish S ^*, Tuncer, Hande H. ^*, Allan, John N., Ujjani, Chaitra S., Barr, Paul M., Brown, Jennifer R. ^*, Eyre, Toby A. ^*, Skarbnik, Alan, Bannerji, Rajat, Eichhorst, Barbara, Brander, Danielle M., Sharmokh, Simon ^*, Jiang, Daniel Dingfeng ^*, Pena, German ^*, Kamalakar, Rajesh ^*, Emechebe, Nnadozie ^*, Pivneva, Irina ^*, Burne, Rebecca ^*, Guerin, Annie ^*, Davids, Matthew S., Mato, Anthony ^*

Source: In Blood 5 November 2020 136 Supplement 1:19-22

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Authors: Gritti, Giuseppe ^*, Marlton, Paula, Phillips, Tycel J., Arthur, Christopher, Bannerji, Rajat, Corradini, Paolo, Johnston, Anna ^*, Seymour, John F., Yuen, Sam, Hirata, Jamie, Musick, Lisa ^*, Saha, Sourish ^*, Croft, Brandon ^*, Flowers, Christopher

Source: In Blood 5 November 2020 136 Supplement 1:45-47

Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors

Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Phase 1b Results of Symphony-1 with 22.5 Months Follow-up

Authors: Salles, Gilles, Park, Steven I., Phillips, Tycel J., Amengual, Jennifer E., Andorsky, David J, Campbell, Philip, McKay, Pamela, Leonard, John P., Chen, Yingxue, Chen, Jade, Bannerji, Rajat, Kapopara, Apoorva, Szanto, Attila, Morschhauser, Franck

Source: In Blood 2 November 2023 142 Supplement 1:3035-3035

Pharmacokinetics, Drug Interaction, and Exposure-Safety Analyses of Tazemetostat When Co-Administered with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Authors: Chen, Yingxue, Bannerji, Rajat, Teng, Renli, Szanto, Attila, Ogier, Julien

Source: In Blood 2 November 2023 142 Supplement 1:6136-6136

Influenza Adherence Tool Kit: Implementation and evaluation among allogeneic hematopoietic transplantation recipients.

Authors: Krimmel, Tracy¹ (NURSE) tracy.krimmel@gmail.com, Bannerji, Rajat², Borysyuk, Maribel³, Schneider, Susan M.⁴ (NURSE)

Source: Clinical Journal of Oncology Nursing. Jun2017, Vol. 21 Issue 3, p339-344. 6p. 3 Charts.

Subject Terms: *INFLUENZA prevention, *CANCER treatment, *CHI-squared test, *HEMATOPOIETIC stem cell transplantation, *INFLUENZA, *INFLUENZA vaccines, *INTELLECT, *MEDICAL records, *PATIENT compliance, *QUESTIONNAIRES, *STATISTICAL sampling, *SCALE analysis (Psychology), *TRANSPLANTATION of organs, tissues, etc., *SPECIALTY hospitals, *THEMATIC analysis, *HUMAN services programs, *PRE-tests & post-tests, *EVALUATION of human services programs, *DESCRIPTIVE statistics

Geographic Terms: NEW Jersey

IBCL-485 A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma

Authors: Salles, Gilles, Shah, Harsh, Leonard, John P., Szanto, Attila, Chen, Jade, Bannerji, Rajat, Morschhauser, Franck, Nastoupil, Loretta J.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S454-S455